Allergy Therapeutics (GB:AGY) has released an update.
Allergy Therapeutics is showing signs of financial recovery with a notable revenue increase in the second half of 2024, marking their first period of growth since 2021. The company has made strides in its R&D programs, achieving significant progress in its Grass MATA MPL and VLP Peanut trials. With strengthened financial support and strategic advancements, Allergy Therapeutics is poised for future success.
For further insights into GB:AGY stock, check out TipRanks’ Stock Analysis page.
